Traitement d'entretien de la maladie de Crohn par la mésalazine par voie orale (Pentasa). Etude contrôlée multicentrique. Groupe d'Etudes thérapeutiques des affections inflammatoires digestives (GETAID).

Translated title of the contribution: Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders

J. P. Gendre, J. Y. Mary, C. Florent, R. Modigliani, J. F. Colombel, J. C. Soulé, J. P. Galmiche, E. Lerebours, L. Descos, J. M. Viteau

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

BACKGROUND: Mesalamine provides a new therapeutic approach in treating Crohn's disease. METHODS: To assess the efficacy and safety of slow-release mesalamine (Pentasa) in maintaining remission in Crohn's disease, 161 patients with inactive disease were randomized to receive either Pentasa (2 g/day) or placebo in a 2-year double-blind, multicenter trial. Two strata were defined according to the duration of their remission: < 3 months (n = 64) or 3-24 months (n = 97), presumed to be high and low relapse risk strata, respectively. RESULTS: The probability of relapse was higher in the short-remission placebo group than in the three other groups (p < 0.003), showing there was a significant benefit from Pentasa in the high relapse risk stratum. In this stratum, the 2-year on-going remission rate was of 29% +/- 9% and 45% +/- 11% (mean +/- SD) in the placebo and Pentasa groups, respectively. The incidences of side effects were similar in both groups. CONCLUSION: Pentasa (2 g/day for 2 years) is a safe and effective maintenance treatment for Crohn's disease when given within 3 months of achieving remission.

Translated title of the contributionMaintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders
Original languageFrench
Pages (from-to)251-256
Number of pages6
JournalAnnales de gastroentérologie et d'hépatologie
Volume29
Issue number5
StatePublished - Oct 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders'. Together they form a unique fingerprint.

Cite this